|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.762 USD | -6.26% |
|
+1.64% | -62.95% |
| Apr. 15 | Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform | CI |
| Apr. 02 | Top Midday Decliners | MT |
Gritstone bio, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was USD 48.21 million compared to USD 4.04 million a year ago. Net loss was USD 75.08 million compared to USD 105.31 million a year ago.
Basic loss per share from continuing operations was USD 0.95 compared to USD 2.79 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -62.95% | 86.49M | |
| -2.86% | 87.31B | |
| +2.63% | 40.86B | |
| -22.17% | 29.36B | |
| +58.56% | 24.49B | |
| -14.42% | 17.31B | |
| -18.90% | 11.62B | |
| -15.61% | 11.31B | |
| -44.02% | 11.26B | |
| +5.17% | 8.31B |
GRITSTONE BIO, INC. 
